Statement: kir2dl1 polymorphism positive is an indication that polymorphism of the kir2dl1 gene has been detected in a sample. Patients must be bedbound or severaly disabled to participate in the primary trial.
Primary_evidence: Inclusion Criteria:   Pathologically confirmed breast cancer, determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy   Locally advanced breast cancer, not stage IV, and with a tumor size >= 2 cm (as measured on imaging or estimated by physical exam)   No obvious contraindications for primary chemotherapy   Residual tumor planned to be removed surgically following completion of neoadjuvant therapy   Able to lie still for 1.5 hours for PET scanning   Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)   Leukocytes >= 3,000/ul   Absolute neutrophil count >= 1,500/ul   Platelets >= 100,000/ul   Total bilirubin within normal institutional limits   Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times the institutional upper limit of normal   Creatinine within normal institutional limits OR creatinine clearance >= 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal   If female, postmenopausal for a minimum of one year, OR surgically sterile, OR not pregnant, confirmed by institutional standard of care (SOC) pregnancy test, and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation   Able to understand and willing to sign a written informed consent document and a Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines Exclusion Criteria:   Previous treatment (chemotherapy, radiation, or surgery) to involved breast; including hormone therapy   Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements   Medically unstable   Condition requiring anesthesia for PET scanning and/or unable to lie still for 1.5 hours   History of allergic reactions attributed to compounds of similar chemical or biologic composition to F-18 fluorothymidine   Pregnant or nursing   Previous malignancy, other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix, from which the patient has been disease free for less than 5 years   Currently on hormone therapy as the primary systemic neoadjuvant therapy